TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22952008

Group type: EXPERIMENTAL
Intervention: 311 nm UVB phototherapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Overall PLE patients (both treated and untreated)
Number of subjects: 23
Study: 20683336

Group type: EXPERIMENTAL
Intervention: Monthly Personal Digital Assistant supported home assessments by PLWAs with clinic appointments every 3 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard of care monthly clinic visits
Number of subjects: 100
Study: 18460033

Group type: EXPERIMENTAL
Intervention: darunavir 400 mg bid plus ketoconazole 200 mg bid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir 400/100 mg bid plus ketoconazole 200 mg bid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ketoconazole 200 mg bid with darunavir/ritonavir
Number of subjects: 0
Study: 15860682

Group type: EXPERIMENTAL
Intervention: Added dead space (400 ml)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Added dead space (400 ml) and 38% O2
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control
Number of subjects: 2
Study: 12970302

Group type: EXPERIMENTAL
Intervention: Sustained release melatonin (1.5 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 10619732

Group type: EXPERIMENTAL
Intervention: Amphotericin B with or without flucytosine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9289453

Group type: EXPERIMENTAL
Intervention: Pregnancy complicated by hypertension (studied group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Healthy pregnant women (control group)
Number of subjects: 62
Study: 1999091

Group type: EXPERIMENTAL
Intervention: Atrioventricular pacing (atrial demand, atrioventricular sequential, atrioventricular universal)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ventricular demand pacing
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atrioventricular pacing
Number of subjects: 40
Study: 31997369

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral analysis system of psychotherapy (CBASP)
Number of subjects: 68
Study: 31526367

Group type: EXPERIMENTAL
Intervention: HIV Exposed Infants testing EIA positive from the 2012-2013 cross-sectional survey
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: HIV-free survival
Number of subjects: 580
Study: 28866864

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age, race, history of cardiovascular diseases, decreased triglycerides, decreased pulse pressure, and albuminuria
Number of subjects: 0

Group type: COMPARATOR
Intervention: General population
Number of subjects: 0
Study: 25759400

Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg/day, titrated from 30 mg after three days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (matched, with sham titration)
Number of subjects: 40
Study: 25607563

Group type: EXPERIMENTAL
Intervention: Active colloidal oatmeal moisturizer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study: 22798265

Group type: EXPERIMENTAL
Intervention: Abatacept (∼10 mg/kg every 4 weeks)
Number of subjects: 317
Study: 19797259

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 0
Study: 17457450

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 429
Study: 15057903

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (IFN) 3 million units three times weekly plus full course of ribavirin (RBV) at 800 mg/day (group A; n = 53)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Interferon alfa‐2b (IFN) 3 million units three times weekly plus 16 weeks of placebo followed by RBV (group B; n = 54)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (IFN) plus RBV (group A)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Interferon alfa‐2b (IFN) plus RBV (group B)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (IFN) plus RBV (group A) with zidovudine (AZT)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (IFN) plus RBV (group A) without zidovudine (AZT)
Number of subjects: 107
Study: 12101381

Group type: EXPERIMENTAL
Intervention: Adjunctive stenting following thrombolytic therapy
Number of subjects: 118
Study: 9523907

Group type: EXPERIMENTAL
Intervention: Sucrose solution (100% energy carbohydrate)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lipid emulsion (100% energy fat, 20% Intralipid)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Non-nutrient control (0.9% saline)
Number of subjects: 9
Study: 7897784

Group type: EXPERIMENTAL
Intervention: 3-day treatment with trimethoprim/sulfamethoxazole (TMP/SMX) - one tablet twice daily for 3 days followed by 7 days of placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 10-day treatment with trimethoprim/sulfamethoxazole (TMP/SMX) - one tablet twice daily for 10 days
Number of subjects: 80
Study: 2795416

Group type: EXPERIMENTAL
Intervention: Polaroid photorefractive screening without cycloplegia
Number of subjects: 187

Group type: COMPARATOR
Intervention: Standard cycloplegic retinoscopy
Number of subjects: 187
Study: 683224

Group type: EXPERIMENTAL
Intervention: Catheter tip at the third to fourth lumbar segment
Number of subjects: 73

Group type: COMPARATOR
Intervention: Catheter tip at the seventh to eighth thoracic segment
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Administration of antibiotics through the catheter
Number of subjects: 73
Study: 31641074

Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC) therapy
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 148
Study: 31399440

Group type: EXPERIMENTAL
Intervention: Intervention group (diabetes prevention program)
Number of subjects: 1163

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1163
Study: 27312537

Group type: EXPERIMENTAL
Intervention: Resilient adolescents (those who experienced war trauma but did not manifest symptoms on the SDQ or CRIES)
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Interventions designed for war-traumatized youth
Number of subjects: 710
Study: 25354241

Group type: EXPERIMENTAL
Intervention: Repeated acupuncture manipulations
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Changes of local perfusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Insertion-only
Number of subjects: 12

Group type: COMPARATOR
Intervention: Single-manipulation
Number of subjects: 12
Study: 23941163

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical equipoise regarding oral anticoagulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relevance of randomized controlled trial
Number of subjects: 0
Study: 22131608

Group type: EXPERIMENTAL
Intervention: MDD women
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 16
Study: 19455483

Group type: EXPERIMENTAL
Intervention: Mood stabilizers (lithium, carbamazepine, divalproex sodium, topiramate, lamotrigine)
Number of subjects: 0
Study: 16939067

Group type: EXPERIMENTAL
Intervention: EC-MPS (720 mg b.i.d.)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: EC-MPS
Number of subjects: 367

Group type: COMPARATOR
Intervention: MMF
Number of subjects: 367
Study: 15208587

Group type: EXPERIMENTAL
Intervention: ADAM33 16-SNP haplotype (frequency, 14.6% in white subjects)
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Two SNPs in strong linkage disequilibrium (T1 and T+1)
Number of subjects: 652
Study: 11042570

Group type: EXPERIMENTAL
Intervention: Surgery followed by one course of perioperative chemotherapy
Number of subjects: 281

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 281
Study: 9130892

Group type: EXPERIMENTAL
Intervention: Tryptorelin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (untreated cells)
Number of subjects: 0
Study: 8453963

Group type: EXPERIMENTAL
Intervention: Pinacidil 25 mg daily for 1 week
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3739562

Group type: EXPERIMENTAL
Intervention: Pimozide (2 to 8 mg per day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29390064

Group type: EXPERIMENTAL
Intervention: Clopidogrel or Ticagrelor (randomized antiplatelet treatment)
Number of subjects: 4354
Study: 27391868

Group type: EXPERIMENTAL
Intervention: FB (formula supplemented with higher DHA and ARA content)
Number of subjects: 96

Group type: COMPARATOR
Intervention: FA (standard infant formula)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Breast milk
Number of subjects: 96
Study: 25937522

Group type: EXPERIMENTAL
Intervention: FOLFOX4 plus cetuximab
Number of subjects: 118

Group type: COMPARATOR
Intervention: FOLFOX4
Number of subjects: 118
Study: 23908302

Group type: EXPERIMENTAL
Intervention: Group A (full ablative laser pretreatment)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Group B (fractional ablative laser pretreatment)
Number of subjects: 10
Study: 21039140

Group type: EXPERIMENTAL
Intervention: DVD group
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Interactive computer module (ICM) group
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study: 19430389

Group type: EXPERIMENTAL
Intervention: diclofenac (1%)
Number of subjects: 50

Group type: COMPARATOR
Intervention: control
Number of subjects: 50
Study: 16930256

Group type: EXPERIMENTAL
Intervention: Artesunate plus standard monotherapies
Number of subjects: 3455

Group type: EXPERIMENTAL
Intervention: PCR-adjusted outcomes
Number of subjects: 3455

Group type: EXPERIMENTAL
Intervention: Crude Day 28 failure rates
Number of subjects: 3455

Group type: EXPERIMENTAL
Intervention: Unresolved infections counted as failures
Number of subjects: 3455

Group type: EXPERIMENTAL
Intervention: Unresolved infections excluded from analysis
Number of subjects: 3455
Study: 12882668

Group type: EXPERIMENTAL
Intervention: 70 degrees lateral decubital trans-abdominal laparoscopic approach
Number of subjects: 30

Group type: COMPARATOR
Intervention: 30 degrees decubital laparoscopic operation
Number of subjects: 30
Study: 11099655

Group type: EXPERIMENTAL
Intervention: Enzyme-converted group-B-to-group-O (ECO) RBCs
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group O RBCs
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ECO RBCs
Number of subjects: 24
Study: 9194107

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin (15 mg/kg twice daily; maximum dosage 750 mg twice daily)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Intravenous ceftazidime plus tobramycin (CAZ/TM) for 14 days
Number of subjects: 108

Group type: COMPARATOR
Intervention: Intravenous ceftazidime plus tobramycin (CAZ/TM)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 108
Study: 1355971

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg orally every 12h for 13 doses and intravenous placebo every 8h (n = 5)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intravenous gentamicin 1.7 mg/kg every 8h for 19 doses and oral placebo every 12h (n = 5)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oral placebo every 12h and intravenous placebo every 8h (n = 4)
Number of subjects: 14
Study: 3030039

Group type: EXPERIMENTAL
Intervention: Beta 1-selective metoprolol (50 mg b.i.d.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-selective propranolol (40 mg b.i.d.)
Number of subjects: 12
Study: 31447126

Group type: EXPERIMENTAL
Intervention: NTHi vaccine
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 28359688

Group type: EXPERIMENTAL
Intervention: Hyaluronic matrix and collagenated heterologous bone graft
Number of subjects: 13

Group type: COMPARATOR
Intervention: Collagenated heterologous bone graft alone
Number of subjects: 13
Study: 26493567

Group type: EXPERIMENTAL
Intervention: CM + CBT (n = 69)
Number of subjects: 116

Group type: COMPARATOR
Intervention: CBT alone (n = 47)
Number of subjects: 116
Study: 23333016

Group type: EXPERIMENTAL
Intervention: 5 × 5 Gy plus 4 Gy boost
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 55.8 Gy in 31 fractions with 5‐FU and leucovorin
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Elderly patients (>69 years)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Local excision (traditional technique, transanal endoscopic microsurgery, Kraske procedure)
Number of subjects: 89
Study: 21942620

Group type: EXPERIMENTAL
Intervention: Nasal PHT (combined 17β‐estradiol plus norethisterone)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Oral PHT (combined 17β‐estradiol plus norethisterone)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Nasal PHT
Number of subjects: 112

Group type: COMPARATOR
Intervention: Oral PHT
Number of subjects: 112

Group type: COMPARATOR
Intervention: Nasal PHT vs Oral PHT
Number of subjects: 112
Study: 20031737

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 300
Study: 17079186

Group type: EXPERIMENTAL
Intervention: Horizontal tracheal incision (H group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Window-type tracheal excision (W group)
Number of subjects: 40
Study: 15367480

Group type: EXPERIMENTAL
Intervention: Nurse-led secondary prevention clinics
Number of subjects: 1343

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1343
Study: 11934203

Group type: EXPERIMENTAL
Intervention: diclofenac sodium
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ketorolac tromethamine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (Endosol)
Number of subjects: 30
Study: 9524395

Group type: EXPERIMENTAL
Intervention: Three‐part intervention aimed at improving communication with the health unit
Number of subjects: 145

Group type: COMPARATOR
Intervention: Usual disease reporting system
Number of subjects: 145
Study: 8023671

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 28

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 28
Study: 3137096

Group type: EXPERIMENTAL
Intervention: 2500 IU hCG intramuscularly on days 3, 6, and 9 after ovulation induction by 10,000 IU of hCG
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (357 ovulation induction cycles)
Number of subjects: 74
Study: 31533663

Group type: EXPERIMENTAL
Intervention: Probiotic capsules (Lactobacillus rhamnosus DSM 14870 and Lactobacillus gasseri DSM 14869) self-administered vaginally once daily for 30 days, then once a week until Day 190.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Probiotic capsules self-administered vaginally after antibiotic treatment in Group 2.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Triple oral antibiotic combination (cefixime 400 mg stat, doxycycline 100 mg BD for 7 days, metronidazole 2 g stat) in Group 2.
Number of subjects: 39

Group type: COMPARATOR
Intervention: No intervention in Group 3 (control group).
Number of subjects: 39
Study: 27449969

Group type: EXPERIMENTAL
Intervention: Intrauterine injection of 1000 IU of hCG before embryo transfer (ET) (n=62)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Placebo group receiving an intrauterine injection of physiological saline before ET (n=49)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group with no intrauterine injection (n=50)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 161
Study: 25479412

Group type: EXPERIMENTAL
Intervention: Noise reduction algorithm ClearVoice
Number of subjects: 20
Study: 23690846

Group type: EXPERIMENTAL
Intervention: Yoga and compassion meditation program (YCMP), 8 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group, untreated, 8 weeks
Number of subjects: 46
Study: 19878123

Group type: EXPERIMENTAL
Intervention: Prostaglandin analogues (latanoprost, travoprost, bimatoprost)
Number of subjects: 129

Group type: COMPARATOR
Intervention: β-blockers (control)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 129
Study: 19165383

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1,200 mg)
Number of subjects: 670

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 670
Study: 16916007

Group type: EXPERIMENTAL
Intervention: Evidence based patient manual
Number of subjects: 249

Group type: COMPARATOR
Intervention: Pamphlet about COPD from the Australian Lung Foundation
Number of subjects: 249
Study: 15109321

Group type: EXPERIMENTAL
Intervention: 3-part targeted resident physician educational program (educational presentation, skills workshop, peer comparison feedback)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 11502639

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol xinafoate powder, 50 microg bid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral montelukast, 10 mg qd
Number of subjects: 0
Study: 9249084

Group type: EXPERIMENTAL
Intervention: AG group (54 g amino acids + 150 g glucose)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: AGG group (AG + 110 g glucose)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: AGF group (AG + 40 g fat)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: AGL group (58 g amino acids + 60 g glycerol)
Number of subjects: 45

Group type: COMPARATOR
Intervention: G group (200 g glucose)
Number of subjects: 45
Study: 8500237

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg daily)
Number of subjects: 804

Group type: COMPARATOR
Intervention: Hydralazine (300 mg daily) plus Isosorbide dinitrate (160 mg daily)
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 804
Study: 3067246

Group type: EXPERIMENTAL
Intervention: Femoxetine (600 mg recommended daily dosage, flexible dosing)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Imipramine (150 mg recommended daily dosage, flexible dosing)
Number of subjects: 52
Study: 31844967

Group type: EXPERIMENTAL
Intervention: 500 mg hesperidin, twice daily for 12 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 30106248

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) combined with one-session treatment (OST)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (PBO) combined with one-session treatment (OST)
Number of subjects: 35
Study: 28498186

Group type: EXPERIMENTAL
Intervention: CQI interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study: 26590813

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 3691

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 3691

Group type: EXPERIMENTAL
Intervention: Tamoxifen or Letrozole
Number of subjects: 3691
Study: 22784013

Group type: EXPERIMENTAL
Intervention: naltrexone 50 mg
Number of subjects: 158

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 158
Study: 21183870

Group type: EXPERIMENTAL
Intervention: IGL-1
Number of subjects: 140
Study: 17953719

Group type: EXPERIMENTAL
Intervention: Levocetirizine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Desloratadine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 16394687

Group type: EXPERIMENTAL
Intervention: Normothermic group (tympanic temperature at 36.5 degrees C)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hypothermic group (tympanic temperature at 34.5 degrees C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups at predicted propofol concentration of 3 microg/ml
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups at predicted propofol concentrations of 3 to 7 microg/ml
Number of subjects: 30
Study: 15288403

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 11751731

Group type: EXPERIMENTAL
Intervention: CHF
Number of subjects: 28
Study: 9423722

Group type: EXPERIMENTAL
Intervention: Endoscopic exploration
Number of subjects: 39

Group type: COMPARATOR
Intervention: Open exploration
Number of subjects: 39
Study: 8494559

Group type: EXPERIMENTAL
Intervention: Continuous exposure to 45-Hz magnetic fields
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intermittent exposure to 45-Hz magnetic fields
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Real exposure first
Number of subjects: 20
Study: 3567002

Group type: EXPERIMENTAL
Intervention: Leicester Micropalliator (1 mg h-1 mandatory background infusion + 2 mg i.v. on-demand bolus doses of morphine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cardiff Palliator (only 2 mg i.v. on-demand bolus doses of morphine)
Number of subjects: 0
Study: 30993537

Group type: COMPARATOR
Intervention: Normal saline (group C)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 10% lidocaine (group L)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 0.3% benzydamine hydrochloride (group B)
Number of subjects: 99
Study: 27476818

Group type: EXPERIMENTAL
Intervention: Corticosteroids (prednisolone 15 mg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 26179201

Group type: EXPERIMENTAL
Intervention: Cediranib (20 mg oral once a day) with cisplatin (25 mg/m2) and gemcitabine (1000 mg/m2) chemotherapy
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo with cisplatin (25 mg/m2) and gemcitabine (1000 mg/m2) chemotherapy
Number of subjects: 124
Study: 23418430

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HT) regimen continued for approximately 2 years (Mean = 1.93 years)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Hormone replacement therapy (HT) regimen discontinued for approximately 2 years (Mean = 1.93 years)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Non-carrier women on hormone replacement therapy (HT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Non-carrier women off hormone replacement therapy (HT)
Number of subjects: 63
Study: 21372447

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (12 weeks)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (9 months)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 37
Study: 19927226

Group type: EXPERIMENTAL
Intervention: Agomelatine 25-50 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 0